Shionogi & Co., Ltd.

4507.T
Drug Manufacturers - Specialty & Generic
2026/11/11 12:12 Updated
Market Cap: $16.5B (¥2.6T)
Stock Price: $19.43 (¥3,080)
Exchange Rate: 1 USD = ¥158.48

Partial Correction to “Quarterly Financial Summary [IFRS] (Consolidated)”

Announced corrections to the Q1 financial summary for the fiscal year ending March 2027. Revised descriptions and certain figures related to cash flows. Revised operating cash flow is 46,318 million yen, and corrected items include equity-method dividend receipts and matters related to the edaravone business.

Importance:
Page Updated: November 11, 2026
IR Disclosure Date: November 11, 2026

Key Figures

  • Operating cash flow after correction: 46,318 million yen
  • Cash and cash equivalents at end of period: 298,937 million yen
  • Payments for business acquisitions: 427,264 million yen

AI要約

Background and Details of the Correction

Shionogi & Co., Ltd. has announced corrections to certain descriptions in the "Quarterly Financial Summary [IFRS] (Consolidated) for the fiscal year ending March 2027, Q1" disclosed in August 2026. The corrections stem from errors in the calculation process of dividend receipts from an equity-method investee and errors in the calculation process of cash flows related to the acquisition of the edaravone business. The corrections affect the "Overview of Business Results, etc." and the "Summary Consolidated Statement of Cash Flows," and the revised figures are presented.

Financial Impact and Outlook

Under the revised figures, operating cash flow has increased and the cash and cash equivalents at the end of the period have risen. Conversely, payments for business acquisitions have expanded significantly, which has material implications for the company’s finances. The corrections relate to line items for the cumulative consolidated period presentation and may affect future disclosures.

This page uses AI to summarize IR materials from TDnet. Please refer to the original document for investment decisions.

Shionogi & Co., Ltd.

Company overview · Stock price · Financial data · All IR

View company page →